Skip to main content

Table 1 Patient Demographics and Treatment Characteristics

From: Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

Demographic or Clinical Characteristic No. of patients %
Median age, years (range) 66 (44.3–83.3)
Median follow-up, months (range) 47.3 (1–76.9)
Gender
 Male 35 76.1
 Female 11 23.9
Histology
 Squamous 22 47.8
 Non-squamous 24 52.2
Performans Status - ECOGa
 0 27 71.1
 1 11 28.9
Missing 8  
Location of relapse
 Central 24 52.2
 Peripheral 22 47.8
In-field relapse
 Yes 29 63
 No 17 37
Primary stage (at first irradiation)
 IIIA 21 45.7
 IIIB 25 54.3
Concurrent chemotherapy at first irradiation
 Yes 35 76.1
 No 11 23.9
Surgery immediately after the first irradiation
 Yes 11 23.9
 No 35 76.1
First irradiation
 Median total dose 66 Gy (44–70)  
 Median dose per fraction 2 Gy (1.8–2.3)  
 Total dose < 60 Gy 7 patients  
 Median BED dose 79.2 Gy (39–90)  
Concomitant chemotherapy (first irradiation)  
 Cisplatin - Docetaxel 17 54.8
 Carboplatin – Paclitaxel 3 9.7
 Cisplatin – Navelbine 3 9.7
 Carboplatin – Etoposide 2 6.5
 Carboplatin - Docetaxel 2 6.5
 Cisplatin – Paclitaxel 1 3.2
 Cisplatin – Etoposide 1 3.2
 Carboplatin – Gemcitabine 1 3.2
 Carboplatin - Navelbine 1 3.2
 Unknown 4  
Reirradiation  
 Median delay between irradiations 22.6 (6.2–101.5)  
 Median tumor size in mm 33 (10–60)  
 Median GTV in mL 13.2 mL (1.1–79.1)  
 Median duration of treatment in days 5 (3–12)  
 Median total physical prescribed dose in Gy 60 (40–75)  
 Median prescribed dose per fraction in Gy 16 (10–20)  
 Median number of sessions 4 (3–5)  
 Median BEDisocenter in Gy 132 (72–187.5)  
 Median BED in Gy 50.2 (6.7–189.1)  
 Isodose of prescription in % 80 (70–83)  
 Median GTV coverage in % 95.6 (43.8–100)
 Median PTV coverage in % 90.2 (34.8–100)
Adjuvant chemotherapy after reirradiation
 Yesa 10 21.7
 No 36 78.3
  1. aAdjuvant chemotherapy consisted in platinum based chemotherapy in 6 and pemetrexed alone in 4 patients